<DOC>
	<DOCNO>NCT02076100</DOCNO>
	<brief_summary>This 3-part study ruzasvir ( MK-8408 ) participant hepatitis C infection . Successive participant enrol dose level evaluate find maximum safe well tolerate dose ruzasvir . Part I participants hepatitis C virus ( HCV ) genotype 3 ( GT3 ) run first : Part II participant HCV genotype 1a ( GT1a ) , Part III participant HCV genotype 2b ( GT2b ) . Parts II III may run concurrently . The primary study hypothesis safe tolerable dose ruzasvir reduce viral load find support clinical investigation .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Pharmacodynamics Ruzasvir ( MK-8408 ) Participants With Hepatitis C Infection ( MK-8408-003 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Body mass index ( BMI ) &gt; =18 &lt; =37 kg/m^2 In general good health , except HCV infection Clinical diagnosis chronic HCV infection exclusively GT3 ( Panels AD ) exclusively GT1a ( Panels EF ) , exclusively GT2b ( Panels GH ) . Must agree follow smoke restriction define CRU Must agree use acceptable method contraception study 90 day last dose ruzasvir Clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary major neurological abnormality diseases History clinically significant hepatic disease , Gilbert 's disease biliary tract disease History cancer ( malignancy ) exception adequately treat nonmelanomatous skin carcinoma carcinoma situ cervix , successfullytreated malignancy â‰¥10 year prior screen History significant multiple and/or severe allergy anaphylactic reaction significant intolerability prescription nonprescription drug food Positive hepatitis B human immunodeficiency virus ( HIV ) Major surgery donate lose 1 unit blood ( approximately 500 mL ) within 4 week prior screen Participated another investigational trial within 4 week prior screen visit QTc interval &gt; =470 msec ( male ) &gt; = 480 msec ( female ) Unable refrain anticipates use medication ( prescription and/or nonprescription ) herbal remedy begin approximately 2 week prior first study drug dose , throughout trial posttrial visit Consumes &gt; 2 glass alcoholic beverage per day Regular user ( include `` recreational use '' ) illicit drug history drug ( include alcohol ) abuse within approximately 12 month Evidence history chronic hepatitis cause HCV Previous treatment HCV NS5A inhibitor MK8742 , daclatasvir , MK8325 Treatment HCV therapy HCV protease Evidence advance decompensated liver disease ; evidence bridge fibrosis high grade fibrosis ( Metavir score &gt; =3 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>